 <h1>Velcade Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>bortezomib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about bortezomib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Velcade.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to bortezomib: powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, bortezomib (the active ingredient contained in Velcade) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking bortezomib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>cough producing mucus</li>
<li>decreased urination</li>
<li>difficult or labored breathing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>fainting</li>
<li>fever</li>
<li>headache</li>
<li>increase in heart rate</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>nerve pain</li>
<li>painful blisters on the trunk of the body</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>rapid breathing</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy nose</li>
<li>sunken eyes</li>
<li>sweating</li>
<li>swollen glands</li>
<li>thirst</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>weakness in the arms, hands, legs, or feet</li>
<li>wrinkled skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Dilated neck veins</li>
<li>general feeling of discomfort or illness</li>
<li>increased sensitivity to pain</li>
<li>increased sensitivity to touch</li>
<li>irregular breathing</li>
<li>irregular heartbeat</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>thickening of bronchial secretions</li>
<li>tingling in the hands and feet</li>
<li>weight gain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>back pain</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>bruising</li>
<li>change in consciousness</li>
<li>coughing or vomiting blood</li>
<li>dark urine</li>
<li>deafness</li>
<li>deep or fast breathing with dizziness, numbness to feet, hands, and around the mouth</li>
<li>diarrhea</li>
<li>drowsiness</li>
<li>fast heartbeat</li>
<li>general tiredness and weakness</li>
<li>irritability</li>
<li>itching</li>
<li>light-colored stools</li>
<li>loss of consciousness</li>
<li>pain in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>persistent bleeding or oozing from puncture sites, mouth, or nose</li>
<li>pounding, slow heartbeat</li>
<li>rectal bleeding</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>restlessness</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>seizures</li>
<li>shaking</li>
<li>stiff neck</li>
<li>stomach pain and tenderness</li>
<li>trouble sleeping</li>
<li>upper right stomach pain</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of bortezomib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>bone pain</li>
<li>difficulty having a bowel movement</li>
<li>difficulty with moving</li>
<li>feeling unusually cold or shivering</li>
<li>hair loss or thinning of hair</li>
<li>heartburn</li>
<li>indigestion</li>
<li>joint pain or swelling</li>
<li>loss of appetite</li>
<li>loss of taste</li>
<li>mental depression</li>
<li>muscle cramps</li>
<li>muscle pain or stiffness</li>
<li>nausea</li>
<li>pain in the arms or legs</li>
<li>rash</li>
<li>stomach discomfort, upset, or pain</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><p>
<!-- end powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bortezomib: injectable powder for injection, intravenous powder for injection</i></p><h3>Gastrointestinal</h3><p>Grade 3 gastrointestinal events were reported to have occurred in 18% of patients and Grade 4 events were reported in 1%.  Gastrointestinal events were considered to be serious in 11% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 64%), diarrhea (up to 51%), constipation (up to 43%), decreased appetite (up to 43%), vomiting (up to 36%), dyspepsia (up to 13%)</p>
<p><b>Frequency not reported</b>: Ascites, dysphagia, fecal impaction, hemorrhagic gastritis, gastrointestinal hemorrhage, hematemesis, paralytic ileus, large intestinal obstruction, paralytic intestinal obstruction, small intestinal obstruction, large intestinal perforation, stomatitis, melena, gastroenteritis, hemorrhagic duodenitis, peritonitis, oral mucosal petechiae, gastroesophageal reflux, acute pancreatitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (34%), neutropenia (27%), anemia (23%), leukopenia (20%), lymphopenia (23%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Lymphadenopathy, febrile neutropenia, pancytopenia, hemolytic anemia, thrombocytopenia purpura</p>
<p><b>Frequency not reported</b>: Disseminated intravascular coagulation, subdural hematoma, pancytopenia, hemolytic anemia, thrombocytopenia purpura<sup>[Ref]</sup></p><p>Thrombocytopenia was characterized by a dose related decrease in platelet count during the dosing period (days 1 through 11) with a return to the baseline platelet count during the rest period (days 12 through 21) of each treatment cycle.  Thrombocytopenia was grade 3 or 4 for 24% and 5% of patients, respectively.</p>
<p></p>
<p>Grade 3 or 4 neutropenia have been reported to have occurred in 9% and 3% of treated patients, respectively.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (39%), paresthesia and dysesthesia (23%), headache (22%), dizziness (17%), dysgeusia (13%), anxiety (10%)</p>
<p><b>Common</b> (1% to 10%): Peripheral sensory neuropathy, tremor</p>
<p><b>Uncommon</b> (0.1% to 1%): Cerebrovascular accident, convulsion, syncope, disturbance in attention, increased activity, ageusia, somnolence, migraine, jerky movements, postural dizziness, sciatica, post herpetic neuralgia, cognitive disorder, mononeuropathy, paresis, restless leg syndrome, speech disorder, intracranial hemorrhage, paraplegia, subarachnoid hemorrhage</p>
<p><b>Postmarketing reports</b>: Autonomic neuropathy, encephalopathy<sup>[Ref]</sup></p><p>Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory.  However, cases of severe sensory and motor peripheral neuropathy have been reported.  Patients with preexisting symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy during treatment with bortezomib.  Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness.  Patients experiencing new or worsening peripheral neuropathy may require change in the dose and schedule of bortezomib.</p>
<p></p>
<p>Following dose adjustments, improvement in or resolution of peripheral neuropathy has been reported in 51% of patients with peripheral neuropathy greater than or equal to grade 2 in the relapsed multiple myeloma study.  Improvement in or resolution of peripheral neuropathy has been reported in 73% of patients who discontinued due to grade 2 neuropathy or who had greater than or equal to grade 3 peripheral neuropathy in the phase 2 multiple myeloma studies.  The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (26%), pain in limb (26%), bone pain (14%), myalgia (14%), muscle cramps (14%), back pain (13%)</p>
<p><b>Common</b> (1% to 10%): Peripheral swelling, muscle weakness, musculoskeletal pain </p>
<p><b>Uncommon</b> (0.1% to 1%): Joint stiffness, buttock pain, joint swelling, muscle spasms, muscle twitching, sensation of heaviness, muscle stiffness, swelling, pain in jaw<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Most reports of hypotension (including orthostatic hypotension) were grade 1 or 2 in severity.  Grade 3 hypotension was reported to have occurred in 3% and Grade 4 hypotension was reported in less than 1% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypotension (13%)</p>
<p><b>Frequency not reported</b>: Aggravated atrial fibrillation, atrial flutter, cardiac amyloidosis, cardiac arrest, congestive cardiac failure, hypertension, myocardial ischemia, myocardial infarction, pericardial effusion, pulmonary edema, angina pectoris, bradycardia, sinus arrest, complete atrioventricular block, pericarditis, Torsades de pointes, decreased left ventricular ejection fraction, ventricular tachycardia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (22%), cough (20%), upper respiratory tract infection (18%), cough (17%), lower respiratory tract/lung infection (15%), nasopharyngitis (14%), pneumonia (12%)</p>
<p><b>Common</b> (1% to 10%): Epistaxis, dyspnea on exertion, rhinorrhea, bronchitis, sinusitis </p>
<p><b>Uncommon</b> (0.1% to 1%): Nasal congestion, wheezing, pleural effusion, hoarseness, chest wall pain, hypoxia, pulmonary congestion, rhinitis, asthma, hyperventilation, orthopnea, sinus pain, throat tightness, productive cough, respiratory alkalosis, respiratory arrest, tachypnea, pneumococcal, bronchopneumonia, pleural infection, pulmonary edema</p>
<p><b>Frequency not reported</b>: Acute respiratory distress syndrome, acute diffuse infiltrative pulmonary disease, atelectasis, exacerbated chronic obstructive airways disease, hemoptysis, pulmonary hypertension, pulmonary alveolar hemorrhage<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (18%), herpes zoster (12%)</p>
<p><b>Very rare</b> (less than 0.01%): Erythematous plaques or nodules on the trunk, generalized morbilliform erythema with ulcerations and fever, cutaneous vasculitis, histiocytoid Sweet Syndrome</p>
<p><b>Frequency not reported</b>: Toxic epidermal necrolysis, leukocytoclastic vasculitis, pruritus, urticaria, facial edema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenic conditions (fatigue, malaise, and weakness) (65%), pyrexia (36%), headache (28%), insomnia (27%), dizziness (excluding vertigo) (21%), dehydration (18%), anxiety (14%), fatigue (15%), dysgeusia (13%), rigors (12%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia</p>
<p><b>Frequency not reported</b>: Impaired hearing, aspergillosis, bacteremia, herpes viral infection, listeriosis, septic shock, toxoplasmosis, oral candidiasis, tumor lysis syndrome, vertigo<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Blurred vision (11%)</p>
<p><b>Common</b> (1% to 10%): Eye pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Dry eye, conjunctivitis, eye discharge, abnormal vision, eye hemorrhage, photophobia, eye irritation, increased lacrimation, conjunctival hyperemia, blepharitis, eye swelling </p>
<p><b>Rare</b> (less than 0.1%): Ophthalmic herpes</p>
<p><b>Frequency not reported</b>: Conjunctival infection, irritation, diplopia</p>
<p><b>Postmarketing reports</b>: Optic neuropathy, blindness<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Stevens-Johnson Syndrome</p>
<p><b>Frequency not reported</b>: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Acute liver failure (in patients receiving multiple concomitant medications and with serious underlying medical conditions)</p>
<p><b>Frequency not reported</b>: Hyperbilirubinemia, cholestasis, hepatic hemorrhage, hepatitis, portal vein thrombosis, asymptomatic increases in liver enzymes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (34 to 43%), dehydration (18%)</p>
<p><b>Common</b> (1% to 10%): Hyper- or hypocalcemia, hypokalemia, decreased weight, increased blood lactate dehydrogenase</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypoglycemia, hyperkalemia, hyperuricemia, hyper or hyponatremia, hypomagnesemia, hypophosphatemia, decreased blood bicarbonate levels, increased blood alkaline phosphatase, urea, blood amylase, and C-reactive protein, increased appetite and weight, cachexia, vitamin B12 deficiency, tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Peripheral neuropathies (50%), insomnia (18 to 27%), neuralgia (23%), anxiety (14%)</p>
<p><b>Common</b> (1% to 10%): Agitation, confusion, depression</p>
<p><b>Uncommon</b> (0.1% to 1%): Delirium, restlessness, mood swings, mental status changes, sleep disorder, irritability, hallucinations, abnormal dreams </p>
<p><b>Frequency not reported</b>: Agitation, confusion, psychotic disorder, mental status change, suicidal ideation<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Acute and chronic renal impairment, dysuria</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p>
<p><b>Frequency not reported</b>: Renal calculus, renal colic, hematuria, proteinuria, difficulty in micturition or micturition urgency, oliguria, bilateral hydronephrosis, bladder spasm, urinary tract infection, hemorrhagic cystitis, proliferative glomerular nephritis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site erythema, catheter related infection, catheter related complication, post procedural pain, post procedural hemorrhage, burns<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Angioedema, laryngeal edema<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Syndrome of Inappropriate Antidiuretic Hormone (SIADH)</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Testicular pain, erectile dysfunction</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Velcade (bortezomib)." Millennium Pharmaceuticals Inc, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Garcia-Navarro X,  Puig L,  Fernandez-Figueras MT,  Dalmau J,  Roe E,  Alomar A "Bortezomib-associated cutaneous vasculitis." Br J Dermatol  (2007):</p><p id="ref_5">5. Murase JE,  Wu JJ,  Theate I,  Cole GW,  Barr RJ,  Dyson SW "Bortezomib-induced histiocytoid Sweet syndrome." J Am Acad Dermatol 60 (2009): 496-7</p><p id="ref_6">6. Kenealy MK,  Prince HM,  Honemann D,  Jaskiewicz AD,  Herrington JD "Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma." Pharmacotherapy 26 (2006): 1205-6</p><p id="ref_7">7. Rosinol L,  Montoto S,  Cibeira MT,  Blade J "Bortezomib-induced severe hepatitis in multiple myeloma: a case report." Arch Intern Med 165 (2005): 464-5</p><p id="ref_8">8. Terpos E,  Politou M,  Rahemtulla A "Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration." J Cancer Res Clin Oncol  (2004):</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Ninlaro vs Velcade, which is better?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Velcade (bortezomib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: proteasome inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
<li>Lymphoma</li>
<li>Mantle Cell Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bortezomib: injectable powder for injection, intravenous powder for injection</i></p><h3>Gastrointestinal</h3><p>Grade 3 gastrointestinal events were reported to have occurred in 18% of patients and Grade 4 events were reported in 1%.  Gastrointestinal events were considered to be serious in 11% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 64%), diarrhea (up to 51%), constipation (up to 43%), decreased appetite (up to 43%), vomiting (up to 36%), dyspepsia (up to 13%)</p><p><b>Frequency not reported</b>: Ascites, dysphagia, fecal impaction, hemorrhagic gastritis, gastrointestinal hemorrhage, hematemesis, paralytic ileus, large intestinal obstruction, paralytic intestinal obstruction, small intestinal obstruction, large intestinal perforation, stomatitis, melena, gastroenteritis, hemorrhagic duodenitis, peritonitis, oral mucosal petechiae, gastroesophageal reflux, acute pancreatitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (34%), neutropenia (27%), anemia (23%), leukopenia (20%), lymphopenia (23%)</p><p><b>Uncommon</b> (0.1% to 1%): Lymphadenopathy, febrile neutropenia, pancytopenia, hemolytic anemia, thrombocytopenia purpura</p><p><b>Frequency not reported</b>: Disseminated intravascular coagulation, subdural hematoma, pancytopenia, hemolytic anemia, thrombocytopenia purpura<sup>[Ref]</sup></p><p>Thrombocytopenia was characterized by a dose related decrease in platelet count during the dosing period (days 1 through 11) with a return to the baseline platelet count during the rest period (days 12 through 21) of each treatment cycle.  Thrombocytopenia was grade 3 or 4 for 24% and 5% of patients, respectively.</p><p></p><p>Grade 3 or 4 neutropenia have been reported to have occurred in 9% and 3% of treated patients, respectively.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (39%), paresthesia and dysesthesia (23%), headache (22%), dizziness (17%), dysgeusia (13%), anxiety (10%)</p><p><b>Common</b> (1% to 10%): Peripheral sensory neuropathy, tremor</p><p><b>Uncommon</b> (0.1% to 1%): Cerebrovascular accident, convulsion, syncope, disturbance in attention, increased activity, ageusia, somnolence, migraine, jerky movements, postural dizziness, sciatica, post herpetic neuralgia, cognitive disorder, mononeuropathy, paresis, restless leg syndrome, speech disorder, intracranial hemorrhage, paraplegia, subarachnoid hemorrhage</p><p><b>Postmarketing reports</b>: Autonomic neuropathy, encephalopathy<sup>[Ref]</sup></p><p>Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory.  However, cases of severe sensory and motor peripheral neuropathy have been reported.  Patients with preexisting symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy during treatment with bortezomib.  Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness.  Patients experiencing new or worsening peripheral neuropathy may require change in the dose and schedule of bortezomib.</p><p></p><p>Following dose adjustments, improvement in or resolution of peripheral neuropathy has been reported in 51% of patients with peripheral neuropathy greater than or equal to grade 2 in the relapsed multiple myeloma study.  Improvement in or resolution of peripheral neuropathy has been reported in 73% of patients who discontinued due to grade 2 neuropathy or who had greater than or equal to grade 3 peripheral neuropathy in the phase 2 multiple myeloma studies.  The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (26%), pain in limb (26%), bone pain (14%), myalgia (14%), muscle cramps (14%), back pain (13%)</p><p><b>Common</b> (1% to 10%): Peripheral swelling, muscle weakness, musculoskeletal pain </p><p><b>Uncommon</b> (0.1% to 1%): Joint stiffness, buttock pain, joint swelling, muscle spasms, muscle twitching, sensation of heaviness, muscle stiffness, swelling, pain in jaw<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Most reports of hypotension (including orthostatic hypotension) were grade 1 or 2 in severity.  Grade 3 hypotension was reported to have occurred in 3% and Grade 4 hypotension was reported in less than 1% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypotension (13%)</p><p><b>Frequency not reported</b>: Aggravated atrial fibrillation, atrial flutter, cardiac amyloidosis, cardiac arrest, congestive cardiac failure, hypertension, myocardial ischemia, myocardial infarction, pericardial effusion, pulmonary edema, angina pectoris, bradycardia, sinus arrest, complete atrioventricular block, pericarditis, Torsades de pointes, decreased left ventricular ejection fraction, ventricular tachycardia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (22%), cough (20%), upper respiratory tract infection (18%), cough (17%), lower respiratory tract/lung infection (15%), nasopharyngitis (14%), pneumonia (12%)</p><p><b>Common</b> (1% to 10%): Epistaxis, dyspnea on exertion, rhinorrhea, bronchitis, sinusitis </p><p><b>Uncommon</b> (0.1% to 1%): Nasal congestion, wheezing, pleural effusion, hoarseness, chest wall pain, hypoxia, pulmonary congestion, rhinitis, asthma, hyperventilation, orthopnea, sinus pain, throat tightness, productive cough, respiratory alkalosis, respiratory arrest, tachypnea, pneumococcal, bronchopneumonia, pleural infection, pulmonary edema</p><p><b>Frequency not reported</b>: Acute respiratory distress syndrome, acute diffuse infiltrative pulmonary disease, atelectasis, exacerbated chronic obstructive airways disease, hemoptysis, pulmonary hypertension, pulmonary alveolar hemorrhage<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (18%), herpes zoster (12%)</p><p><b>Very rare</b> (less than 0.01%): Erythematous plaques or nodules on the trunk, generalized morbilliform erythema with ulcerations and fever, cutaneous vasculitis, histiocytoid Sweet Syndrome</p><p><b>Frequency not reported</b>: Toxic epidermal necrolysis, leukocytoclastic vasculitis, pruritus, urticaria, facial edema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenic conditions (fatigue, malaise, and weakness) (65%), pyrexia (36%), headache (28%), insomnia (27%), dizziness (excluding vertigo) (21%), dehydration (18%), anxiety (14%), fatigue (15%), dysgeusia (13%), rigors (12%)</p><p><b>Common</b> (1% to 10%): Pyrexia</p><p><b>Frequency not reported</b>: Impaired hearing, aspergillosis, bacteremia, herpes viral infection, listeriosis, septic shock, toxoplasmosis, oral candidiasis, tumor lysis syndrome, vertigo<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Blurred vision (11%)</p><p><b>Common</b> (1% to 10%): Eye pain</p><p><b>Uncommon</b> (0.1% to 1%): Dry eye, conjunctivitis, eye discharge, abnormal vision, eye hemorrhage, photophobia, eye irritation, increased lacrimation, conjunctival hyperemia, blepharitis, eye swelling </p><p><b>Rare</b> (less than 0.1%): Ophthalmic herpes</p><p><b>Frequency not reported</b>: Conjunctival infection, irritation, diplopia</p><p><b>Postmarketing reports</b>: Optic neuropathy, blindness<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Stevens-Johnson Syndrome</p><p><b>Frequency not reported</b>: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Acute liver failure (in patients receiving multiple concomitant medications and with serious underlying medical conditions)</p><p><b>Frequency not reported</b>: Hyperbilirubinemia, cholestasis, hepatic hemorrhage, hepatitis, portal vein thrombosis, asymptomatic increases in liver enzymes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (34 to 43%), dehydration (18%)</p><p><b>Common</b> (1% to 10%): Hyper- or hypocalcemia, hypokalemia, decreased weight, increased blood lactate dehydrogenase</p><p><b>Uncommon</b> (0.1% to 1%): Hypoglycemia, hyperkalemia, hyperuricemia, hyper or hyponatremia, hypomagnesemia, hypophosphatemia, decreased blood bicarbonate levels, increased blood alkaline phosphatase, urea, blood amylase, and C-reactive protein, increased appetite and weight, cachexia, vitamin B12 deficiency, tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Peripheral neuropathies (50%), insomnia (18 to 27%), neuralgia (23%), anxiety (14%)</p><p><b>Common</b> (1% to 10%): Agitation, confusion, depression</p><p><b>Uncommon</b> (0.1% to 1%): Delirium, restlessness, mood swings, mental status changes, sleep disorder, irritability, hallucinations, abnormal dreams </p><p><b>Frequency not reported</b>: Agitation, confusion, psychotic disorder, mental status change, suicidal ideation<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Acute and chronic renal impairment, dysuria</p><p><b>Uncommon</b> (0.1% to 1%): Increased blood creatinine</p><p><b>Frequency not reported</b>: Renal calculus, renal colic, hematuria, proteinuria, difficulty in micturition or micturition urgency, oliguria, bilateral hydronephrosis, bladder spasm, urinary tract infection, hemorrhagic cystitis, proliferative glomerular nephritis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site erythema, catheter related infection, catheter related complication, post procedural pain, post procedural hemorrhage, burns<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Angioedema, laryngeal edema<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Syndrome of Inappropriate Antidiuretic Hormone (SIADH)</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Testicular pain, erectile dysfunction</p><p id="ref_1">1. "Product Information. Velcade (bortezomib)." Millennium Pharmaceuticals Inc, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Garcia-Navarro X,  Puig L,  Fernandez-Figueras MT,  Dalmau J,  Roe E,  Alomar A "Bortezomib-associated cutaneous vasculitis." Br J Dermatol  (2007):</p><p id="ref_5">5. Murase JE,  Wu JJ,  Theate I,  Cole GW,  Barr RJ,  Dyson SW "Bortezomib-induced histiocytoid Sweet syndrome." J Am Acad Dermatol 60 (2009): 496-7</p><p id="ref_6">6. Kenealy MK,  Prince HM,  Honemann D,  Jaskiewicz AD,  Herrington JD "Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma." Pharmacotherapy 26 (2006): 1205-6</p><p id="ref_7">7. Rosinol L,  Montoto S,  Cibeira MT,  Blade J "Bortezomib-induced severe hepatitis in multiple myeloma: a case report." Arch Intern Med 165 (2005): 464-5</p><p id="ref_8">8. Terpos E,  Politou M,  Rahemtulla A "Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration." J Cancer Res Clin Oncol  (2004):</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Ninlaro vs Velcade, which is better?</li>
</ul><h2>More about Velcade (bortezomib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: proteasome inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
<li>Lymphoma</li>
<li>Mantle Cell Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>